Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis

Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis ... Read More